NSCLC (NON-SMALL CELL LUNG CANCER)
Clinical trials for NSCLC (NON-SMALL CELL LUNG CANCER) explained in plain language.
Never miss a new study
Get alerted when new NSCLC (NON-SMALL CELL LUNG CANCER) trials appear
Sign up with your email to follow new studies for NSCLC (NON-SMALL CELL LUNG CANCER), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Breakthrough targeted therapy trial offers hope for Tough-to-Treat lung cancer
Disease control Not yet recruitingThis study is testing whether a new targeted drug called JMKX001899 works better than standard chemotherapy (docetaxel) for people with advanced lung cancer that has a specific genetic change called KRAS G12C. The trial will involve about 472 adults whose cancer has worsened afte…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE3 • Sponsor: Jemincare • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
Can chemotherapy stop immunotherapy from backfiring in lung cancer?
Disease control Not yet recruitingThis study is for people with advanced non-small cell lung cancer (NSCLC) who have a specific biomarker that puts them at high risk for a dangerous side effect called hyperprogression, where immunotherapy can cause tumors to grow much faster. Researchers want to see if starting t…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Università Vita-Salute San Raffaele • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug duo aims to shrink lung tumors before surgery
Disease control Not yet recruitingThis study is testing whether a combination of two drugs, sacituzumab govitecan and toripalimab, can shrink tumors in patients with a specific type of lung cancer before they have surgery. The goal is to see if this pre-surgery treatment helps remove more of the cancer and lowers…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
New drug combo aims to shrink tumors before lung cancer surgery
Disease control Not yet recruitingThis study is testing whether a high dose of the drug firmonertinib, combined with bevacizumab, can effectively shrink tumors before surgery in patients with a specific type of lung cancer (EGFR-mutated, non-small cell). The goal is to see if this pre-surgery treatment helps remo…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New hope for lung cancer patients when First-Line drugs fail
Disease control Not yet recruitingThis study is testing whether combining two drugs, sacituzumab tirumotecan and furmonertinib, can help control advanced non-small cell lung cancer that has specific genetic changes (EGFR mutations) and has started growing again after initial treatment. It will involve about 45 ad…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
New triple-threat approach aims to shrink lung tumors before surgery
Disease control Not yet recruitingThis study is testing whether a three-part treatment given before surgery can better eliminate cancer cells in patients with operable non-small cell lung cancer. The treatment combines a short, precise course of radiation (SBRT) with two immunotherapy drugs and standard chemother…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated Mar 06, 2026 15:38 UTC
-
Scientists search for clues in lung cancer tumors
Knowledge-focused Not yet recruitingThis study aims to understand how immune system markers in tumor samples relate to treatment response in advanced lung cancer patients receiving standard immunochemotherapy. Researchers will analyze small tumor samples collected before treatment, during treatment, and if the canc…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Sponsor: Technische Universität Dresden • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:43 UTC